

## Skeletal Effects of Raloxifene and Targeted Tibial Loading in the KK/Ay Murine Model of Type II Diabetes

<sup>1</sup>Nusaiba N. Chowdhury<sup>1</sup>, Rachel K. Suroweic<sup>1,3</sup>, Olivia N. Reul<sup>1</sup>, Rachel K. Kohler<sup>1</sup>, Dyann M. Segvich<sup>1</sup>, Robert N. Bone<sup>2</sup>, Joseph M. Wallace<sup>1</sup>



<sup>1</sup>Department of Biomedical Engineering, Indiana University-Purdue University Indianapolis (IUPUI), Indianapolis, IN, USA

<sup>2</sup>Islet and Physiology Core, Indiana University, School of Medicine (IUSM), Indiana University, IN, USA


<sup>3</sup>Anatomy, Cell Biology and Physiology, Indiana University School of Medicine (IUSM), Indianapolis, IN, USA

#### Introduction

- Type 2 Diabetes (T2D) affects an estimated 9.1% of the US population.
- Patients with T2D have a higher fracture risk compared to non-diabetes individuals.
- Raloxifene (RAL) is an FDA-approved drug that can reduce fracture risk by improving bone structure and increasing tissue hydration which in turn enhances bone quality and ductility..
- In-vivo mechanical loading is a potent anabolic stimulus that can induce bone formation and increase bone mass.

#### Goals

- 1) Are the biochemistries and bone phenotype of the KK/Ay genetic mutation mouse model reflective of the human condition of Type 2 diabetes?
- 2) What are the therapeutic effects of RAL, targeted mechanical loading, and the combined effects of RAL + mechanical loading on the T2D phenotype.




- 4 to 17 wks: Weekly body weights and blood glucose measurements were obtained.
- **12 wks:** Mice were euthanized (n=4/grp) and used for **strain gage calibration** to determine the loaded required to achieve 2050με of tension during cyclic loading tibiae.
- 13 wks to 17 wks: All mice underwent in-vivo tibial loading 3x/wk. Half of the mice from each group were also subcutaneously injected with 0.5mg/kg of RAL 5x/wk.
  - ➤ Males: 80 total 40 KK/Ay (n=20 RAL, n=20 UN) and 40 CON (n=20 RAL, n=20 UN).
  - Females: 80 total 40KK/Ay (n=20 RAL, n=20 UN) and 40 CON (n=20 RAL, n=20 UN).
- 17 wks: Glucose Tolerance Tests (GTT) and Insulin Tolerance Tests (ITT) (n=6/grp).
- **18 wks:** Mice were **euthanized** via cardiac puncture. Whole blood, kidney, pancreas, bi-lateral tibiae were harvested.

#### **Pending:**

- Serum: Blood Urea Nitrogen (BUN), Parathyroid Hormone (PTH), Calcium, Phosphorous, Creatinine.
- Pancreas: beta-cell mass.
- Mechanical tests: 4-point bending tests (n=12/grp), fracture toughness test (n=6/grp).

#### Acknowledgments

- This work is supported by NIH/NIAMS AR072609
- The authors would like to thank the Translation Core at Indiana University School of Medicine (IUSM), Indianapolis, IN for performing the hbA1c and serum insulin assays.



**Figure 1: Body weights** – comparable between groups in both sexes, increases throughout the period of the study; lower average values are observed in mice administered with RAL, starting at 13wks of age, compared to UN. **Blood glucose** – KK/Ay have higher average values compared to CON. Both KK/Ay and CON males are severely hyperglycemic, but only KK/Ay females demonstrate severe hyperglycemia.

# 

**Figure 2:** Micro-computed tomography ( $\mu$ CT) –  $8\mu$ m voxel size. **Cortical Thickness** – significantly higher for loaded compared to non-loaded in both males and females; significantly higher with RAL compared to UN; significant differences in cortical thickness between KK/Ay and CON in females only. **Trabecular BV/TV** – significantly higher for non-loaded compared to loaded; significantly higher with RAL compared to UN; significant differences in BV/TV between KK/Ay and CON in males only. 3-way ANOVA used for statistical analysis. Additional cortical and trabecular data pending.

Variable	Genotype	Treatment	Loading	Interactions
		MALES		
Cortical	<b>D</b> C	ns	Loaded 个	2000
Thickness	ns		(p<0.0001)	none
Trabecular	KK/Ay ↑	RAL 个	Loaded 个	2000
BV/TV	(p=0.0294)	(p<0.0001)	(p<0.0001)	none
		FEMALES		
Cortical	VV / Λ., Ι	RAL 个	Loaded 个	Loading x
	KK/Ay ↓ (n <0.0001)			Genotype
Thickness	(p<0.0001)	( p<0.0001)	(p<0.0001)	(p<0.0001)
Trabecular		RAL 个	Loaded 个	
BV/TV	ns	(p<0.0001)	(p=0.0211)	none

**Table 1:** Summary of statistical Analysis for Cortical Thickness and Trabecular BV/TV using 3-way ANOVA





Figure 3: AUC of GTT – M: no interactions; main effects: RAL  $\uparrow$  (p=<0.0001), KK/Ay  $\uparrow$  (p=0.0297); \*p=0.0223, \*\*\*p=0.0070, p<0.0001. F: No interaction; main effects: RAL  $\uparrow$  (p=0.0005), KK/Ay  $\uparrow$  (p<0.0001); post-hoc comparison: \*\*p=0.0031, \*\*\*p=0.0006, \*\*\*\*p<0.0001. AUC of ITT – M: no interactions, no main effects. F: no interactions; main effects: KK/Ay  $\downarrow$  (p<0.0001); post-hoc comparison: \*\*\*p=0.0004, \*\*\*\*p<0.0001. 2-way ANOVA used for statistical analysis.



**Figure 4:** hbA1c − M: no interactions; main effects: RAL  $\downarrow$  (p=0.0038), KK/Ay  $\uparrow$  (p<0.0001); post-hoc comparison: \*p=0.0223, \*\*p=0.0070, \*\*\*\*p<0.0001. **F:** no interaction; main effects: KK/Ay  $\uparrow$  (p<0.0001); post-hoc comparison: \*\*\*\*p<0.0001. **Serum insulin** − **M:** no interaction; main effects: KK/Ay  $\downarrow$  (p=0.0143). **F:** no interactions; main effects: KK/Ay  $\uparrow$  (p<0.0001); post-hoc comparison: \*\*\*\*p<0.0001. 2-way ANOVA used for statistical analysis.

### **CONCLUSION**

- The data supports the use of the KK/Ay model as a suitable model for the study of Type-II diabetes.
- The blood glucose values are higher in KK/Ay compared to CON in both males and females.
- Serum insulin confirms that the mice are still producing insulin, which is characteristic of early stages of Type-II Diabetes. This is in contrast with Type-I, which is characterized by completed destruction of beta-cells and inability to produce insulin.
- Cortical thickness and trabecular BV/TV increased with loading indicating that T2D does not diminish mechanosensitivity.
- RAL increased cortical thickness and BV/TV in both CON and KK/Ay.